Publications by authors named "Gabriele D Gallina"
: Systemic lupus erythematosus (SLE) is associated with infection-related morbidity. The risk of adverse outcomes secondary to infections was exacerbated during the recent COVID-19 pandemic, prompting mass vaccination with the novel mRNA-based and viral-vectored vaccines. Limited data exist on the long-term impact of vaccination in patients with SLE.
View Article and Find Full Text PDFStep-down treatment with mepolizumab for eosinophilic granulomatosis with polyangiitis: a real-life single-centre study.
Rheumatology (Oxford)
September 2025
Objectives: To evaluate the efficacy and safety of a step-down treatment approach using mepolizumab for eosinophilic granulomatosis with polyangiitis (EGPA) in a real-life single-centre cohort. The study aimed to assess outcomes following a transition from high-dose (300 mg/4 weeks) to low-dose (100 mg/4 weeks) mepolizumab after achieving remission.
Methods: This retrospective study included EGPA patients treated with mepolizumab between April 2014 and December 2024.
Article Synopsis
- Systemic lupus erythematosus (SLE) leads to immune dysfunction and increased infection susceptibility, often resulting in infection-associated flares (IAFs) that can resolve alongside infections.
- In a study of 2,039 visits, researchers identified 134 flares (17% yearly deterioration of lupus low disease activity state [LLDAS]), with 38 classified as IAFs primarily linked to bacterial and herpesvirus infections.
- IAFs showed similar or greater severity in symptoms compared to other flares, with distinct characteristics such as lower anti-DNA antibody levels in viral IAFs, indicating the need for further research to explore these differences and improve treatment approaches.